No Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23

Figure 2

The levels of CD41a and CD31 MPs did not differ among psoriatic patients with comorbidities and without comorbidities.